For the quarter ending 2025-09-30, EYPT had $3,434K increase in cash & cash equivalents over the period. -$60,152K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -59,732 | -104,621 |
| Depreciation of property and equipment | 576 | 1,035 |
| Amortization of debt discount and premium and discount on available-for-sale marketable securities | -951 | -2,934 |
| Stock-based compensation | 6,428 | 14,696 |
| Deferred income tax | 0 | -90 |
| Accounts receivable and other current assets | 3,134 | -3,248 |
| Other assets | 24 | 62 |
| Inventory | -568 | 373 |
| Accounts payable and accrued expenses | -3,058 | 1,504 |
| Right-of-use assets and operating lease liabilities | -19 | 543 |
| Deferred revenue | 0 | -28,637 |
| Other noncurrent liabilities | -8 | -18 |
| Net cash (used in) provided by operating activities | -59,354 | -115,709 |
| Purchases of marketable securities | 9,817 | 93,368 |
| Sales and maturities of marketable securities | 66,000 | 182,725 |
| Purchases of property and equipment | 798 | 1,496 |
| Net cash (used in) provided by investing activities | 55,385 | 87,861 |
| Proceeds from issuance of stock | 6,658 | - |
| Payment of equity issue costs | 0 | 291 |
| Net settlement of stock units to satisfy statutory tax withholding | 133 | 1,237 |
| Proceeds from exercise of stock options and employee stock purchase plan | 905 | 866 |
| Principal payments on finance lease obligations | 27 | 51 |
| Net cash (used in) provided by financing activities | 7,403 | -713 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | 3,434 | -28,561 |
| Cash and cash equivalents at beginning of period | 99,854 | - |
| Cash and cash equivalents at end of period | 74,727 | - |
EyePoint Pharmaceuticals, Inc. (EYPT)
EyePoint Pharmaceuticals, Inc. (EYPT)